RSV vaccine to be offered to premature babies in NI
A long-acting injection is to be offered for eligible children from this autumn.
RSV is a common, but highly infectious, respiratory virus that affects the breathing system, particularly in young children and older adults.
It infects 90% of children by the age of two and is one of the leading causes of hospitalisation in the first year of life.
An RSV vaccine has been available to pregnant women in Northern Ireland since last September and is offered from 28 weeks of pregnancy.
The new programme will cover those infants born very prematurely and too early to benefit from the RSV vaccination given to their mothers.
The single Nirsevimab injection offers about 80% protection and replaces Palivizumab, which gives 55% protection and is administered up to five times.
It follows advice from the Joint Committee on Vaccination and Immunisation.
Chief Medical Officer Sir Michael McBride said: "Vaccinations have been extremely effective in eradicating diseases and protecting children and other vulnerable groups from serious illness and death.
"Worryingly, we are now seeing a decline in the uptake of childhood immunisations.
"Vaccinations offer children the very best start in life. Quite simply, if children aren't vaccinated, they're not protected."
Health Minister Mike Nesbitt said the new vaccine would strengthen winter preparedness in the health service and reduce pressures on GPs, emergency departments and hospital admissions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
9 minutes ago
- Fast Company
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last year, the High Court ruled that one of Moderna's patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech's Comirnaty vaccine had infringed it, meaning Moderna is entitled to damages in relation to sales after March 2022. The High Court also ruled that the other Moderna patent under challenge in the case was invalid. Moderna was refused permission to appeal against that decision. But Pfizer and BioNTech were granted permission to appeal in an attempt to try and invalidate Moderna's second patent and appealed earlier this month, arguing Moderna's developments of mRNA technology were obvious developments of previous work, rendering the patent invalid. Judge Richard Arnold, however, rejected Pfizer and BioNTech's appeal. Pfizer and BioNTech said in a joint statement that the decision 'does not change our unwavering stance that this patent is invalid' and the companies will seek to appeal. 'This decision has no immediate impact on Pfizer and BioNTech or Comirnaty,' the companies added. Moderna did not immediately respond to a request for comment. Friday's decision in the latest ruling in the legal dispute between the two sides over their competing vaccines, which helped save millions of lives during the pandemic. The companies have also been involved in proceedings in Germany – where a court ruled in Moderna's favour in March – the United States Patent Office, which held that two Moderna COVID-19 vaccine patents were invalid, and elsewhere.
Yahoo
38 minutes ago
- Yahoo
Young carers face higher risks of depression, anxiety and lost futures – and most receive no support
In developed countries, around 12% of young people provide regular, unpaid care for a family member. It's work that's essential, often invisible – and potentially devastating to their mental health. As more families rely on these young carers, many are left without legal protections, recognition, or the support they urgently need. Across Europe, informal carers now provide up to 80% of all long-term care. This figure is rising sharply due to ageing populations, an increase in chronic illness, and advances in medical technology. Between 2000 and 2050, the demand for unpaid care is expected to grow by 50% in Europe alone, with similar trends emerging in the US and Australia. As adult carers struggle to meet rising demand, children, teenagers and young adults are stepping into the breach. These young carers often take on domestic, emotional, practical and personal care tasks that would challenge any adult. While some report growing resilience, maturity and empathy, the long-term toll on education, mental health and physical wellbeing is increasingly hard to ignore. Lost opportunities, lasting consequences Globally, young carers face significant restrictions on their education and career prospects. In both the UK and Germany, research shows that young adult carers are less likely to complete university, less likely to secure employment and more likely to experience long-term unemployment than their peers. These disadvantages aren't just financial – they're linked to increased rates of depression and anxiety later in life. The social cost is high, too. Young carers are more likely to face bullying, isolation and limited opportunities for friendship or leisure. Chronic illness in the household can increase stress, leading to economic hardship, family breakdown and domestic conflict. Mental health is caught in the crossfire: many young carers experience psychological distress, depression and even self-harm. Along with colleagues, I published a study that underscored the urgency of this issue. Our research showed that young carers in high-income countries are significantly more likely than their peers to experience poor mental health, including anxiety, depression and severe emotional distress. Not all care is equal – and neither are its effects. The intensity, type and duration of caregiving matter greatly. Young carers who provide personal care, dedicate more hours each week, or have cared for a longer period are at the greatest risk of mental health difficulties. Girls and young women are particularly vulnerable. They are overrepresented among young carers and are more likely to take on intensive or prolonged responsibilities. These disparities don't end in childhood. As young adults, female carers tend to experience lower educational attainment and less workforce participation than their male counterparts – disadvantages that have ripple effects on their long-term mental and economic wellbeing. Invisible and unsupported Despite their growing numbers, young carers are often invisible to schools, healthcare providers and policymakers. Most European countries provide no formal recognition, rights or protections. Even though the European parliament addressed the issue in 2018 and 2022, young carers remain absent from key EU frameworks. The UK is a notable exception, with specific rights and national interventions for young carers. But gaps remain. A 2016 report found that nearly one in three young carers identified by local authorities received no support at all. In the US, the situation is worse: a lack of national data means young carers are missing entirely from most political conversations and care agendas. Yet support makes a difference. Studies show that recognition and perceived support, whether from teachers, friends, professionals or government policies, can protect young carers' mental health and improve their long-term outcomes. Support can take many forms: respite care, school accommodations, financial assistance, mentoring, or even a simple acknowledgement that their role matters. Without intervention, the personal and societal costs are substantial: deteriorating mental health, lost educational and career opportunities and increased economic dependency in adulthood. If we fail to support young carers, we fail an entire generation of quiet caregivers – and risk undermining the sustainability of our health and care systems for decades to come. Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences. This article is republished from The Conversation under a Creative Commons license. Read the original article. Aoife Bowman Grangel receives funding from the Irish Research Council.
Medscape
39 minutes ago
- Medscape
Chemotherapy Linked to Brain Atrophy in Breast
Patients with breast cancer who undergo chemotherapy may face an increased risk for brain atrophy and cognitive decline, new findings from a pilot study suggested. Memory problems in patients with cancer may not stem solely from stress or anxiety related to their diagnosis but could reflect underlying changes in brain structure, study investigator Paul Edison, PhD, MPhil, professor of neuroscience and clinical professor of neurology at Imperial College London, London, England, told Medscape Medical News . While the findings suggest that chemotherapy may contribute to neuronal damage, the researchers noted that many aspects of the relationship between treatment and brain changes remain unclear. Edison highlighted three key areas that require further investigation — uncovering the mechanisms driving brain atrophy, determining the proportion of patients affected, and identifying effective prevention strategies. Another investigator on the study, Laura Kenny, MD, PhD, associate professor and consultant medical oncologist at Imperial College London, noted that the issue has received limited attention to date but expressed hope that the findings will raise awareness and encourage further research, given its clinical importance. The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025. Investigating Cognitive Impact Advances in chemotherapeutic agents have improved survival rates in patients with cancer. However, challenges persist regarding the long-term impact of these drugs. Chemotherapy-associated cognitive impairment, often referred to as 'brain fog' or 'chemobrain,' affects approximately one third of patients with breast cancer following treatment. While cognitive decline resolves within 12 months for some patients, others experience persistent effects that may elevate the risk for neurodegenerative conditions, Edison explained. To evaluate the impact of chemotherapy on the brain, investigators studied 328 women with nonmetastatic breast cancer who had undergone chemotherapy within the past 12 months. Patients received either anthracycline — a drug derived from the Streptomyces peucetius bacterium — or taxanes such as docetaxel and paclitaxel, both commonly used in breast cancer treatment, or a combination of these agents. In addition, some patients may also have had hormone therapy at some point during treatment, said Kenny. Participants completed neurocognitive prescreening tests every 3 months using a specialized artificial intelligence-driven platform, allowing them to take detailed memory assessments online from home. Among those prescreened, 18 individuals with lower neurocognitive scores (mean age, approximately 55 years) and 19 cognitively normal control individuals without breast cancer (mean age, approximately 67 years) underwent comprehensive, in-person, neurocognitive evaluations and MRI scans. Researchers analyzed the scans using region of interest (ROI) and voxel-based morphometry (VBM), which uses sophisticated computer software, to assess grey matter volumes and surface areas. The ROI analysis revealed significant reductions in gray matter volume (measured in mm3) and surface area (measured in mm2) among patients experiencing chemobrain, particularly affecting the isthmus cingulate and pars opercularis, with changes extending into the orbitofrontal and temporal regions. Significant Atrophy The VBM analysis confirmed significant atrophy in the frontal, parietal, and cingulate regions of patients with chemobrain compared with control individuals ( P < .05). Edison noted that this pattern overlaps with brain changes typically observed in Alzheimer's disease and vascular cognitive impairment. For both analyses, 'we demonstrated there is some amount of shrinkage in the brain among patients with chemobrain.' he said. 'The fact that controls are older means the results are even more significant as there's more brain atrophy as people age.' Some of the affected brain regions may be linked to impaired memory, a hallmark of Alzheimer's disease, but Edison cautioned that given the small sample size this finding should be interpreted with caution. While the analysis demonstrated overall lower brain volumes in patients with 'chemobrain' compared with controls, Edison emphasized that this finding reflects a single time point and does not indicate brain shrinkage over time. Other events, including stroke — can also cause brain changes. Edison highlighted the importance of determining the significance of these brain changes, how they affect patients and whether they can be prevented. In-person neurocognitive testing revealed significantly reduced semantic and verbal fluency, as well as lower Mini-Mental State Examination scores in patients with chemobrain. Edison noted that these results support the MRI findings. The team plans to follow patients to track brain changes and memory recovery, Kenny said. While patients with breast cancer are a common focus, the researchers intend to expand the study to other cancers in both men and women, said Kenny. Anecdotally, many patients report memory problems during chemotherapy, she added. Based on discussions with her oncology colleagues, Kenny noted that many patients anecdotally report experiencing memory problems during chemotherapy. More Research Needed Commenting for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president, Scientific Engagement, at the Alzheimer's Association, said the research may help shed light on why women are more likely to develop dementia than men. For years now, experts have been trying to figure out what puts women at higher risk for AD and other dementias, said Edelmayer. 'We still don't understand whether this involves biologically driven risk factors or socially driven risk factors.' Research linking treatments for other health conditions to increased memory problems may offer some clues, she noted, suggesting a potential avenue for further investigation into the intersection of chemotherapy and neurodegenerative diseases such as Alzheimer's. However, Edelmayer emphasized that this line of research is still in its infancy. Much more work is needed to determine whether there is a direct cause-and-effect relationship with specific chemotherapy drugs, and whether some patients may already be predisposed or at higher risk for cognitive decline, she said. Also commenting for Medscape Medical News , Eric Brown, MD, associate scientist and associate chief of geriatric psychiatry at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada, raised concerns about the study's design. One issue, he noted, is that the researchers did not image all patients who received chemotherapy but instead selected those with the most significant cognitive impairment. As a result, the findings may not have reflected outcomes in the average post-chemotherapy patients but rather represent the most severely affected subgroup. Brown also pointed out that the study did not clarify whether this subgroup had comorbid conditions. It's possible, he said, that some individuals may have had Alzheimer's disease or other forms of dementia unrelated to chemotherapy. He agreed that tracking longitudinal changes in both cognitive scores and neuroimaging — comparing patients who receive chemotherapy with those who do not — would be a valuable next step.
